Sanofi’s bispecific scores in respiratory diseases but fails in eczema
Two of Sanofi’s lunsekimig Phase II trials have met their primary endpoints in respiratory disease, while a study in atopic…
Dermatology
-
-
Lilly’s Ebglyss shows AD benefit in children as young as six months
Eli Lilly’s Ebglyss (lebrikizumab-lbkz) has reduced the severity of atopic dermatitis (AD) in children as young as six months, with…
-
Pfizer’s trispecific heads to Phase III on mid-stage AD success
American pharmaceutical giant Pfizer is planning to take its trispecific antibody, tilrekimig, to Phase III in atopic dermatitis (AD) as…
-
Nektar’s stock rises 51% on Phase II Rezpeg AD maintenance win
Nektar Therapeutics stock has rallied 51% after its lead asset, rezpeg (rezpegaldesleukin), demonstrated potential across monthly and quarterly maintenance dosing…
-
Sanofi’s Dupixent successor heads to regulators after Phase III success
Sanofi has debuted the long-awaited results from two Phase III studies of its potential Dupixent (dupilumab) successor, amlitelimab, in atopic…
-
New data links eczema to inflammatory bowel and eye conditions
Eczema, also known as dermatitis, is a skin condition characterised by dry, itchy, and inflamed skin. Its symptoms can impact…
-
Lilly and Incyte to seek approval of alopecia JAK inhibitor in children
Eli Lilly and Incyte’s oral JAK inhibitor has shown benefit in hair regrowth in paediatric patients with severe alopecia areata.…
-
MoonLake’s IL-17 inhibitor falls short of Bimzelx in HS trial
MoonLake Immunotherapeutics’s stock has crashed after its hidradenitis suppurativa (HS) candidate did not beat UCB’s Bimzelx (bimekizumab-bkz) in a pair…
-
J&J and Protagonist’s oral plaque psoriasis drug bests BMS’ Sotyktu
Johnson & Johnson (J&J) and Protagonist Therapeutics’ icotrokinra has outperformed BMS’s Sotyktu (deucravacitinib) in treating patients with moderate-to-severe plaque psoriasis.…
-
EADV 25: Sanofi’s brivekimig success in Phase IIa HS trial
Sanofi’s brivekimig met the primary endpoint in a Phase IIa trial in patients naïve to biologics with moderate-to-severe hidradenitis suppurativa…
